Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_3
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Not yet recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

terminated133%
not_yet_recruiting133%
suspended133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

NCT06525389
terminatedphase_1

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

NCT04194034
suspendedphase_1

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

NCT01562626

Clinical Trials (3)

Showing 3 of 3 trials
NCT06525389Phase 3

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Not Yet Recruiting
NCT04194034Phase 1

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Terminated
NCT01562626Phase 1

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Suspended

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3